Figure 9
Comparison of different doxorubicin-based treatments. C57BL/6 mice were inoculated with 5 × 105/mouse of MOSEC/luc tumor cells. Four days later, MOSEC/luc tumor-bearing mice were treated with 2 × 106/mouse of doxorubicin (100 μg/ml)-treated, irradiated MOSEC tumor cells. The concentration of doxorubicin inside doxorubicin-treated MOSEC cells was determined as described in the Materials and Methods. Comparable amount of doxorubicin to that found collectively inside 2 × 106 of doxorubicin (100 μg/ml)-treated MOSEC cells was set as 0.5 mg/kg (10 μg/mouse). Another group MOSEC/luc tumor-bearing mice were treated intraperitoneally with 0.5 mg/kg of doxorubicin alone for comparison. A group of MOSEC/luc tumor-bearing mice without treatment was used as a control (naïve). Survival analysis of the different mice groups was also performed. (A) Representative bioluminescence images of MOSEC/luc tumor-bearing mice treated with the different doxorubicin-based treatments. (B) Line graph illustrating the measured values of luminescent intensity in the different groups of mice. (C) Kaplan-Meier survival analysis of MOSEC/luc tumor-bearing mice treated with the doxorubicin-based treatments compared to the control groups.